跳至主要内容
临床试验/NCT02681445
NCT02681445已完成不适用

Non-invasive TB Triage and Patient Mapping Platform Using Breath Via Low-Cost Titanium Dioxide Nanotube Sensor

University of Utah1 个研究点 分布在 1 个国家目标入组 810 人开始时间: 2016年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
810
试验地点
1
主要终点
Correlation of sensor ability to detect breath biomarkers for TB

研究概览

简要总结

The purpose of this pilot study is to evaluate the sensitivity and specificity of a nanotube-based point-of-care breath-based tuberculosis screening test as compared to the current standards of care including sputum microscopy, sputum culture, chest X-ray, and GeneXpert (MTB/RIF).

The primary objective is to determine an initial estimate of the sensitivity and specificity of a nano-tube based point-of-care test for the diagnosis and screening of active pulmonary tuberculosis.

Secondary objectives include the collection of user data to test and further develop the screening platform based on end-user feedback.

详细描述

TB is an infectious disease caused by various strains of mycobacteria. It typically infects the lungs and is spread through the air when an infected patient sneezes, coughs, or spits. When this occurs, the TB bacilli are propelled into the air in droplets that can remain suspended for long periods of time. An individual simply needs to inhale a small amount of bacilli to become infected.

Conventional methods for TB detection and diagnosis are traditionally performed in laboratories or hospitals. For example, the most common method for diagnosis of TB is the acid fast staining of a sputum sample which is then followed by a sputum smear microscopy test. However a disadvantage with the sputum smear test is its poor sensitivity, which is estimated to be at 70%. Additionally, the sensitivity of sputum smear spectroscopy in field settings has been shown to be much lower (35%), especially in populations that have high rates of TB and HIV coinfection. Culturing of mycobacterium from sputum samples is a more sensitive technique. Sputum samples are collected and cultured in either solid media or liquid media looking for the presence of the mycobacterium. However this methodology takes time to conduct (3-4 weeks for solid cultures, and 10-14 days for liquid cultures), which makes it difficult to employ in low resource settings that are typically far from testing facilities.

Recently, other technologies have been developed including fluorescence microscopy for smear tests (10% more sensitive than light microscopy), LED fluorescent microscopy for inexpensive imaging equipment that can be used in the field without the need for a darkroom, and rapid culturing techniques to reduce incubation time. Despite all the improvements that have been made in TB diagnosis, no simple inexpensive POC test is currently available. The techniques mentioned above either focus on variations of microscopy or culture technique. In either case, these methods require lab facilities and highly trained personnel that typically are not available in many rural or low resource areas.

Recent research has shown that various strains of the mycobacteria produce distinct gaseous volatile biomarkers that can be used as a methodology for detecting and identifying the mycobacterium. Specifically, Syhre and Chambers found that Mycobacterium tuberculosis and Mycobacterium bovis cultures give off four specific volatile organic biomarkers (VOBs): methyl phenylacetate, methyl p-anisate, methyl nicotinate, and o-phenylanisole. These compounds were detectable before the visual appearance of colonies, which could have implications in detection of latent TB infection. Syhre et al. were able to detect statistically significant differences of methyl nicotinate in the breath of smear positive TB patients when compared to healthy (smear negative) subjects. Analyses in these studies were done using gas chromatography/mass spectroscopy analysis tools. While they are effective in identifying and quantifying complex gas samples, they are expensive, bulky, and not appropriate for point of care (POC) diagnostics.

These challenges associated with the diagnosis of TB are significant as TB is the second leading cause of death due to a single infectious organism and is responsible for 1.3 million deaths annually (over 3,500 every day), according to the WHO. Overall, an estimated 2 billion people are currently infected worldwide with 8.6 million new active infections occurring each year.[8] Each of these individuals can transmit the disease to 10 to 15 people per year and face a mortality rate of 50% if untreated. The economic burden of TB is staggering as the World Bank estimates that high burden countries can lose up to 7% of GDP due to productivity losses from TB patients and their caretakers. It is so critical that the World Bank committed $100 million to testing for and treating TB in India in 2014 alone.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • No TB Symtoms No history of TB Negative Mantoux test Normal Chest X-ray HIV Negative

排除标准

  • Prior history of TB

结局指标

主要结局

Correlation of sensor ability to detect breath biomarkers for TB

时间窗: 12 Months

Assess feasability of TB sensor to detect breath biomarkers from patients.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Swomitra Mohanty

Assistant Professor

University of Utah

研究点 (1)

Loading locations...

相似试验